Peptide-Conjugated Nanocarriers for Sustained Ocular Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering anti-angiogenic proteins, such as Avastin and Lucentis, to treat conditions like wet macular degeneration and diabetic retinopathy are inefficient due to short half-lives, requiring frequent injections, which are painful and increase the risk of complications, and existing nanocarriers are difficult to sterilize, toxic, or break down into inflammatory fragments.
Innovation Solution
Biodegradable nanocarriers with a net positive surface charge, provided by covalently attached peptides, that adhere to poly-anionic carbohydrates in the vitreous humor, allowing for slow diffusion and controlled release of therapeutic proteins or peptides, extending the time between injections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If anti-angiogenic proteins are injected into vitreous humor, then therapeutic effect is achieved, but frequent re-injection is required due to short half-life
Solution Approach 1:
The patent applies preliminary action by pre-attaching anchoring peptides to the nanocarrier surface before injection. These anchoring peptides covalently bind to poly-anionic carbohydrates in the vitreous humor, establishing anchorages in advance that slow subsequent diffusion and extend the residence time of the therapeutic protein, thereby reducing injection frequency
Solution Approach 2:
The patent uses anchoring peptides as intermediaries between the nanocarrier and the vitreous humor environment. These peptides mediate the interaction by covalently attaching to poly-anionic carbohydrates (such as hyaluronic acid) in the vitreous humor, creating a bridging mechanism that retards nanocarrier diffusion and prolongs therapeutic protein residence time without requiring frequent re-injection
2Reliability
If frequent injections are administered, then therapeutic efficacy is maintained, but patient burden and risk of complications increase
Solution Approach 1:
The anchoring peptides are pre-conjugated to the nanocarrier surface before administration, establishing retention mechanisms in advance. This preliminary action ensures that once injected, the therapeutic protein remains localized in the vitreous humor for extended periods (half-life extended to over 240 days), maintaining therapeutic efficacy while eliminating the need for frequent painful injections and reducing patient burden and complication risks
3Ease of manufacture
If existing nanocarriers are used, then drug delivery is achieved, but sterilization difficulty and toxicity issues arise
Solution Approach 1:
The patent applies parameter changes by modifying the nanocarrier surface properties through covalent attachment of anchoring peptides containing multiple L-arginine residues. This creates a net positive surface charge (zeta potential +2 to +20 mV) that enables electrostatic interaction with poly-anionic carbohydrates in the vitreous humor. The biodegradable composition and surface modification parameters ensure sterilization ease while minimizing toxicity and inflammatory responses
Solution Approach 2:
The patent uses composite materials by combining biodegradable nanocarrier core materials with anchoring peptide surface modifiers. The composite structure consists of the nanocarrier core (providing drug loading and biodegradability) and the anchoring peptide layer (providing positive surface charge and covalent binding capability to vitreous humor carbohydrates). This composite approach achieves effective drug delivery with improved sterilization characteristics and reduced toxicity compared to existing nanocarriers
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanocarriers achieve prolonged residence in the eye, reducing the frequency of injections and minimizing adverse effects, with a half-life of over 240 days, while maintaining therapeutic efficacy and safety.
Implementation Method 1
The biodegradable nanocarriers having a net positive surface charge and zeta potential between about +2 to about +20 mV adhere to poly-anionic carbohydrates when injected in vivo and thus diffuse slowly from their injection site
Implementation Method 2
the ester bond between the amino alcohol and the dicarboxylic acid spontaneously hydrolyzes to break down at predictable rates over many weeks or months
Data Source
AI summary
Disclosed are biodegradable nanocarriers that have a net positive surface charge and zeta potential between about +2 to about +20 mV. The positive surface charge of the nanocarriers is provided by peptides that are covalently attached to the surface of the nanocarriers. The nanocarriers may comprise a drug and may be administered for localized and sustained delivery of the drug.